Articles tagged "Graft function"

2022 American Transplant Congress
Improvement in Kidney Function After Early Conversion to Belatacept-Based Regimen in Allografts with Biopsy-Proven Donor Vascular Disease
T. Ommert¹, J. Javier¹, J. Jackson¹, C. Klein²
¹Piedmont Transplant Institute, Piedmont Atlanta Hospital, Atlanta, GA, ²Piedmont Transplant Institute, Atlanta, GA
*Purpose: Donor arteriosclerosis in the kidney allograft predicts poorer graft outcomes and is a risk factor for tacrolimus-induced nephrotoxicity. Belatacept conversion has been utilized as…
2022 American Transplant Congress
Normal Saline vs Electrolyte-a Use Peri- and Post-Operatively in Adult Kidney Transplant Recipients
K. R. Szempruch, A. D. Martschenko, H. Arora, R. Isaak, R. Prasad, P. Serrano
UNC Medical Center, Chapel Hill, NC
*Purpose: 0.9% normal saline (NS) has been used as the standard fluid replacement in kidney transplant recipients (KTRs) to prevent dehydration and to improve renal…
2022 American Transplant Congress
Defining the Characteristics and Graft Outcomes of Kidney Transplant Recipients with Pre-Transplant Elevated Plasma Oxalate Levels
D. Khan, N. Zhang, M. Keddis
Mayo Clinic, Scottsdale, AZ
*Purpose: The objective of this study is to compare graft outcomes for patients with pre-transplant elevated plasma oxalate (Pox) compared to a matched cohort.*Methods: Kidney…
2022 American Transplant Congress
A Sign of Things to Come? Clinical Markers After Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients
D. T. Kim¹, E. J. Henricksen², B. M. Zhang³, J. J. Teuteberg¹, Y. Moayedi⁴, H. I. Luikart¹, J. Han⁵, B. Wayda¹, K. Khush¹
¹Cardiology, Stanford University, Stanford, CA, ²Transplant, Stanford Health Care, Stanford, CA, ³Pathology, Stanford University, Stanford, CA, ⁴Cardiology, University Health Network, Toronto, ON, Canada, ⁵Cardiology, University of Chicago, Chicago, IL
*Purpose: Endomyocardial biopsy (EMBx) has historically been the standard of care for surveillance post heart transplant (HTx), but is limited by sample area and interpretation.…
2022 American Transplant Congress
Single Nuclei RNA-Sequencing Identifies Distinct Cell Profile in Kidney Allografts with Recurrent Focal Segmental Glomerular Sclerosis (FSGS)
L. Gallon¹, E. Bardhi², J. McDaniels², A. Shetty², P. Hallack¹, C. Kuscu³, C. Kuscu³, T. Rousselle², J. Eason³, D. Maluf², V. Mas²
¹NWU, Chicago, IL, ²University of Maryland, Baltimore, MD, ³UTHSC, Memphis, TN
*Purpose: Strong evidence suggests that primary FSGS is due to a plasma factor that results in general podocyte dysfunction and risk of recurrence after kidney…
2022 American Transplant Congress
Early Experience with 4-drug Maintenance Immunosuppression in Kidney and Pancreas Transplant Recipients
S. Mouawad¹, C. Shoemaker², J. Geyston³, A. Nishio Lucar³
¹University of Virginia Health System, Charlottesville, VA, ²Pharmacy, UVA Health, Charlottesville, VA, ³University of Virginia, Charlottesville, VA
*Purpose: Belatacept based immunosuppression regimens in kidney transplant recipients have been associated with better kidney function, improved metabolic profile, less de novo DSA formation and…
2022 American Transplant Congress
Generation and Functional Characterization of Bio-Engineered Livers for Heterotopic Implantation in Porcine Model of Acute Liver Failure
A. A. Katane¹, B. P. Amiot², A. R. Stumbras¹, A. Mendenhall¹, N. R. Palumbo¹, A. C. Donepudi¹, J. J. Ross¹, S. L. Nyberg³
¹Miromatrix Medical Inc, Eden Prairie, MN, ²Department of Surgery, Mayo Clinic, Rochester, MN, ³William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN
*Purpose: Liver transplantation has shown to be an effective therapy for the end-stage liver diseases (ESLD). However, as donor organ shortages increase, organ engineering technology…
2022 American Transplant Congress
Outcomes After Deceased Donor Kidney Transplantation Utilizing Kidney Allografts with Marginal Perfusion Parameters: A Single-Center Experience
P. N. Chotai¹, A. Logan², F. Siddiqui³, A. Schenk⁴, G. Bumgardner⁵, G. L. Brock², A. El-Hinnawi⁵, A. Rajab⁶, K. Washburn⁷, N. Singh²
¹Division of Transplantation, Department of General Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³Ohio State University, Bloomfield, NJ, ⁴Ohio State University Wexner Medical Center, Bexley, OH, ⁵Ohio State University, Columbus, OH, ⁶Ohio State University Wexner Medical Center, Columbus, OH, ⁷The Ohio State University, Columbus, OH
*Purpose: To study outcomes of deceased donor kidney transplantation (DDKT) in recipients of kidney allografts with poor perfusion parameters.*Methods: This is a retrospective, single center…
2022 American Transplant Congress
High Incidence Of Anti-HLA DSA And Late Allograft Dysfunction In Solid Organ Transplant Recipients Hospitalized With Covid-19
J. T. Killian, S. Roman Soto, V. Hauptfeld-Dolejsek, E. B. Levitan, P. M. Porrett, V. Kumar, F. E. Lund, J. A. Houp
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Solid organ transplant (SOT) recipients admitted for COVID-19 commonly experience immunosuppression reduction and acute allograft dysfunction. Given the number of SOT patients hospitalized for…
2022 American Transplant Congress
TNX-1500, an Fc-Modified Anti-cd154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival
S. Miura¹, Z. Abady¹, F. Pollok¹, M. Ma¹, K. Kinoshita¹, S. Fogarty², P. Maguire², B. Daugherty², S. Lederman², R. Pierson III¹
¹Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, ²Tonix Pharmaceuticals, Chatham, NJ
*Purpose: Blockade of the CD40/CD154 T cell costimulation pathway is a promising approach to replace current clinical immunosuppression. TNX-1500 (TNX) is a novel humanized anti-CD154…